NACDS Marketplace In Brief
This article was originally published in The Tan Sheet
Executive Summary
Dr. Reddy's readies OTC omeprazole launch: Dr. Reddy's prepares to launch its omeprazole 20.6 mg OTC proton pump inhibitor, the equivalent to AstraZeneca's Prilosec OTC, by the end of July. Milan Kalawadia, associate director of the Hyderabad, India-based firm's North American investor relations, did not comment on which retailers will carry the product, but said it will sell in 14-, 28- and 42-count blister packs, the same as the branded product. At the National Association of Chain Drug Stores Marketplace trade show in Boston June 30, Dr. Reddy's senior director of OTC marketing, John Segura, said the firm is "looking forward to" the launch after getting "both FDA approval and the resolution of a lawsuit" to get there. FDA approved Dr. Reddy's abbreviated new drug application June 5 and a court ruled against AstraZeneca's patent-infringement challenge to Dr. Reddy's private-label product (1"The Tan Sheet" March 23, 2009). A final decision is pending on AstraZeneca's appeal of the ruling, but Dr. Reddy's plans to launch the product. "While any launch prior to a final decision is technically at risk, we are confident that we do not infringe any patents asserted against us," Kalawadia said
You may also be interested in...
NACDS New Products In Brief
Bayer launches non-fizz Alka-Seltzer: Bayer HealthCare launches July 15 Alka-Seltzer Plus Fast Crystal Packs, a "taste-free, fizz-free powder that transforms many beverages, such as juice, tea and water, into powerful cold medicine," according to Allyson Daly, senior manager of the firm's global public relations and internal communication. Bayer showcased the product, along with others, at the National Association of Chain Drug Stores' Marketplace trade show in June (1"The Tan Sheet" July 13, 2009). The products are available in 10-count packages with a suggested retail price between $5.59 and $7.29 in most major retailers and in 4-count packages in select retailers for $2.99. Advertising includes television and nationwide sampling in stores and other venues
Bayer Reboots Heart Advantage With Promotion For Aspirin
Revised labeling for Heart Health Advantage, with phytosterols, suggests the product “can be added to an aspirin regimen” after a similarly branded aspirin/phytosterol combo was pulled from the market in April because FDA called it an unapproved new drug.
Bayer Looks To Quick Release Crystals To Shine Light On Aspirin Brand
As private label OTCs threaten brand name stalwarts in the deepening economic recession, Bayer hopes to galvanize its iconic aspirin line with a powdered delivery format in single-dose pouches